BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 38358781)

  • 1. Discovery of a proliferation essential gene signature and actin-like 6A as potential biomarkers for predicting prognosis and neoadjuvant chemotherapy response in triple-positive breast cancer.
    Li X; Luo S; Fu W; Huang M; Huang X; Kang S; Zhang J; Wang Q; Song C
    Cancer; 2024 Apr; 130(S8):1435-1448. PubMed ID: 38358781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Actin-like 6A predicts poor prognosis of hepatocellular carcinoma and promotes metastasis and epithelial-mesenchymal transition.
    Xiao S; Chang RM; Yang MY; Lei X; Liu X; Gao WB; Xiao JL; Yang LY
    Hepatology; 2016 Apr; 63(4):1256-71. PubMed ID: 26698646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the 12-Gene Molecular Score and the 21-Gene Recurrence Score as Predictors of Response to Neo-adjuvant Chemotherapy in Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
    Soliman H; Wagner S; Flake DD; Robson M; Schwartzberg L; Sharma P; Magliocco A; Kronenwett R; Lancaster JM; Lanchbury JS; Gutin A; Gradishar W
    Ann Surg Oncol; 2020 Mar; 27(3):765-771. PubMed ID: 31907749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic and chemotherapeutic response prediction by proliferation essential gene signature: Investigating POLE2 in bladder cancer progression and cisplatin resistance.
    Yu L; Lin N; Ye Y; Zhou S; Xu Y; Chen J; Zhuang W; Wang Q
    J Cancer; 2024; 15(6):1734-1749. PubMed ID: 38370377
    [No Abstract]   [Full Text] [Related]  

  • 5. Notch-based gene signature for predicting the response to neoadjuvant chemotherapy in triple-negative breast cancer.
    Omar M; Nuzzo PV; Ravera F; Bleve S; Fanelli GN; Zanettini C; Valencia I; Marchionni L
    J Transl Med; 2023 Nov; 21(1):811. PubMed ID: 37964363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular types and neoadjuvant chemotherapy in patients with breast cancer- while molecular shifting is more common in luminal a tumors, the pathologic complete response is most frequently observed in her-2 like tumors.
    Salim DK; Mutlu H; Eryilmaz MK; Musri FY; Tural D; Gunduz S; Coskun HS
    Asian Pac J Cancer Prev; 2014; 15(21):9379-83. PubMed ID: 25422228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Actin-like Protein 6A Expression Correlates with Cancer Stem Cell-like Features and Poor Prognosis in Ovarian Cancer.
    Chen PM; Wong CN; Wong CN; Chu PY
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TOPK: A new predictor of the therapeutic response to neoadjuvant chemotherapy and prognosis in triple-negative breast cancer.
    Wang K; Chai J; Xu J; Wei J; Li P; Liu Y; Ma J; Xu T; Zhao D; Yu K; Fan L; Yan Q; Guo S; Li M; Wang Z
    Pathol Res Pract; 2021 Oct; 226():153603. PubMed ID: 34500374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TTK predicts triple positive breast cancer prognosis and regulates tumor proliferation and invasion.
    Gao YH; Qu SS; Cao LQ; Yao M
    Neoplasma; 2022 Mar; 69(2):274-282. PubMed ID: 34846157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathological and prognostic value of TIL and PD L1 in triple negative breast carcinomas.
    Uğurluoğlu C; Yormaz S
    Pathol Res Pract; 2023 Oct; 250():154828. PubMed ID: 37778126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA-543 inhibits the proliferation, migration, invasion, and epithelial-mesenchymal transition of triple-negative breast cancer cells via down-regulation of ACTL6A gene.
    Wang YL; Liang RH; Wang CY; Zhang RP; Wu SY; Han X; Zhang GL
    Clin Transl Oncol; 2022 Jan; 24(1):84-92. PubMed ID: 34181232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular portraits and trastuzumab responsiveness of estrogen receptor-positive, progesterone receptor-positive, and HER2-positive breast cancer.
    Zhao S; Liu XY; Jin X; Ma D; Xiao Y; Shao ZM; Jiang YZ
    Theranostics; 2019; 9(17):4935-4945. PubMed ID: 31410192
    [No Abstract]   [Full Text] [Related]  

  • 13. Tumor infiltrating neutrophil might play a major role in predicting the clinical outcome of breast cancer patients treated with neoadjuvant chemotherapy.
    Geng SK; Fu SM; Ma SH; Fu YP; Zhang HW
    BMC Cancer; 2021 Jan; 21(1):68. PubMed ID: 33446143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Actin-like protein 6A is a novel prognostic indicator promoting invasion and metastasis in osteosarcoma.
    Sun W; Wang W; Lei J; Li H; Wu Y
    Oncol Rep; 2017 Apr; 37(4):2405-2417. PubMed ID: 28260090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EarlyR signature predicts response to neoadjuvant chemotherapy in breast cancer.
    Buechler SA; Gökmen-Polar Y; Badve SS
    Breast; 2019 Feb; 43():74-80. PubMed ID: 30502641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SPAG5 as a prognostic biomarker and chemotherapy sensitivity predictor in breast cancer: a retrospective, integrated genomic, transcriptomic, and protein analysis.
    Abdel-Fatah TMA; Agarwal D; Liu DX; Russell R; Rueda OM; Liu K; Xu B; Moseley PM; Green AR; Pockley AG; Rees RC; Caldas C; Ellis IO; Ball GR; Chan SYT
    Lancet Oncol; 2016 Jul; 17(7):1004-1018. PubMed ID: 27312051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-L1 expression in tumor lesions and soluble PD-L1 serum levels in patients with breast cancer: TNBC versus TPBC.
    Yazdanpanah P; Alavianmehr A; Ghaderi A; Monabati A; Montazer M; Tahmasbi K; Farjadian S
    Breast Dis; 2021; 40(1):43-50. PubMed ID: 33523034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proliferation rate and breast cancer subtype, but not ALDH1 expression, predict pathological response to neoadjuvant chemotherapy in locally advanced breast cancer.
    Chatterjee D; Bal A; Das A; Singh G
    Virchows Arch; 2015 Sep; 467(3):303-10. PubMed ID: 26063415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA methylation changes in response to neoadjuvant chemotherapy are associated with breast cancer survival.
    Pedersen CA; Cao MD; Fleischer T; Rye MB; Knappskog S; Eikesdal HP; Lønning PE; Tost J; Kristensen VN; Tessem MB; Giskeødegård GF; Bathen TF
    Breast Cancer Res; 2022 Jun; 24(1):43. PubMed ID: 35751095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ACTL6A expression promotes invasion, metastasis and epithelial mesenchymal transition of colon cancer.
    Zeng Z; Yang H; Xiao S
    BMC Cancer; 2018 Oct; 18(1):1020. PubMed ID: 30348114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.